Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study.
暂无分享,去创建一个
[1] J. Haller,et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. , 2014, Ophthalmology.
[2] P. Mitchell,et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. , 2014, Ophthalmology.
[3] Kang Zhang,et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). , 2013, Ophthalmology.
[4] Usha Chakravarthy,et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial , 2013, The Lancet.
[5] Q. Nguyen,et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. , 2013, Ophthalmology.
[6] P. Rockwell,et al. Signaling through the vascular endothelial growth factor receptor VEGFR-2 protects hippocampal neurons from mitochondrial dysfunction and oxidative stress. , 2013, Free radical biology & medicine.
[7] Glenn J Jaffe,et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. , 2013, Ophthalmology.
[8] Allen C Ho,et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.
[9] P. Khaw,et al. VEGF-A Is Necessary and Sufficient for Retinal Neuroprotection in Models of Experimental Glaucoma , 2013, The American journal of pathology.
[10] E. Souied,et al. MULTIMODAL EVALUATION OF FOVEAL SPARING IN PATIENTS WITH GEOGRAPHICATROPHY DUE TO AGE-RELATED MACULAR DEGENERATION , 2013, Retina.
[11] P. Campochiaro,et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. , 2013, JAMA ophthalmology.
[12] A. Ho,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[13] E. Souied,et al. Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration , 2012, British Journal of Ophthalmology.
[14] U. Schmidt-Erfurth,et al. RETREATMENT WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY BASED ON CHANGES IN VISUAL ACUITY AFTER INITIAL STABILIZATION OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 3-Year Follow-up Results , 2012, Retina.
[15] Ursula Schmidt-Erfurth,et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. , 2012, Ophthalmology.
[16] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[17] G. Ying,et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: 2-Year Results: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group‡* , 2012 .
[18] W. Freeman,et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. , 2012, Ophthalmology.
[19] P. Campochiaro,et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. , 2012, Ophthalmology.
[20] P. Campochiaro,et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. , 2011, Ophthalmology.
[21] U. Schmidt-Erfurth,et al. Performance of OCT segmentation procedures to assess morphology and extension in geographic atrophy , 2011, Acta ophthalmologica.
[22] Jennifer K. Sun,et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. , 2011, Ophthalmology.
[23] P. Rosenfeld,et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. , 2011, Ophthalmology.
[24] R. Klein,et al. Prevalence of age-related macular degeneration in the US population. , 2011, Archives of ophthalmology.
[25] P. Campochiaro,et al. Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells , 2010, Journal of cellular physiology.
[26] Magali Saint-Geniez,et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris , 2009, Proceedings of the National Academy of Sciences.
[27] Frederick L Ferris,et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. , 2009, Archives of ophthalmology.
[28] Kenneth P. Roos,et al. Autocrine VEGF Signaling Is Required for Vascular Homeostasis , 2007, Cell.
[29] David T. Shima,et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. , 2007, The American journal of pathology.
[30] P. Heiduschka,et al. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. , 2007, American journal of ophthalmology.
[31] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[32] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[33] Benita J. O’Colmain,et al. Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.
[34] P. Campochiaro,et al. Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes. , 2015, American journal of ophthalmology.
[35] Glenn J Jaffe,et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. , 2015, Ophthalmology.
[36] Glenn J Jaffe,et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. , 2014, Ophthalmology.
[37] P. Campochiaro,et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. , 2014, Ophthalmology.
[38] P. Campochiaro,et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. , 2011, Ophthalmology.
[39] Mark Michels,et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. , 2009, Ophthalmology.